

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Plasma cell neoplasms | D054219 | — | — | 2 | — | — | — | — | 2 |
| Multiple myeloma | D009101 | — | C90.0 | 1 | — | — | — | — | 1 |
| Smoldering multiple myeloma | D000075122 | — | — | 1 | — | — | — | — | 1 |
| Melanoma | D008545 | — | — | 1 | — | — | — | — | 1 |
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | — | — | — | — | 1 |
| Neoplasms | D009369 | — | C80 | 1 | — | — | — | — | 1 |
| Drug common name | CITARINOSTAT |
| INN | citarinostat |
| Description | Citarinostat is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against histone deacetylase 6. In addition, it is known to target histone deacetylase 8, histone deacetylase 2, histone deacetylase 1, and histone deacetylase 3. |
| Classification | Small molecule |
| Drug class | enzyme inhibitors: histone deacetylase inhibitors |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | O=C(CCCCCCNC(=O)c1cnc(N(c2ccccc2)c2ccccc2Cl)nc1)NO |
| PDB | — |
| CAS-ID | 1316215-12-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3693786 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 441P620G3P (ChemIDplus, GSRS) |

